Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDAexit?

Executive Summary

Six former FDA commissioners called for the next administration or Congress to make the US food and drug agency a body independent of the Departments of Health and Human Services and Agriculture – insisting such a move could help cut through red tape in fulfilling its public health mission of regulating medical products.

You may also be interested in...



Senate 'Cures' Companion Advances; Funding Unclear

A set of 19 bills aimed at improving the efficiency and pace at which the FDA and the National Institutes of Health (NIH) do their work is now on its way the full Senate for consideration after the chamber's Health, Education, Labor and Pensions (HELP) Committee agreed during an April 6 markup session on the remaining pieces of legislation.

'Cures' adopted; mandatory NIH, FDA funds survive challenge

In a 344-77 vote on 10 July, the US House passed legislation intended to overhaul the US biomedical enterprise, with the aim of accelerating the discovery, development and approval processes for medical products – the 21st Century Cures Act (HR 6).

After long battle, FDA OK's Teva Plan B One-Step without Rx, age restrictions

The US FDA on 20 June said it would permit Teva to sell its single-pill emergency contraceptive Plan B One-Step (1.5 mg levonorgestrel tablet) without a prescription or age restrictions – ending a battle that stretched across three administrations, pitting scientists against policymakers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel